Before an MRI or MRA is performed, Gadolinium-based contrast agents are injected into a vein to enhance the quality of magnetic resonance imaging. Since 2006, medical communities and patients began questioning the safety of GBCAs. Since its FDA approval in 1987, various medical issues have come to light concerning Gadolinium’s use in MRIs.
Gadolinium Deposition Disease (GDD) is an incurable disease linked to the use of gadolinium-based contrast agents during MRI procedures. GDD refers to a patient who experiences persistent medical symptoms that arise even after just one dose of GBCA. The symptoms may last for a few hours to for two months or longer. In cases of GDD, no preexistent disease or subsequently developed disease is present to account for symptoms.
Gadolinium retention is the persistence of gadolinium in the body for a period of time exceeding the standard expulsion. High retention rates of gadolinium have been found mostly in linear brands of the drug. With normal functioning kidneys, the bulk of gadolinium injected should be expelled from the body through urine and feces within two hours. The rest of the substance is expelled over the next few days—within 96 hours. However, studies have shown that some forms of GBCAs persist in the body’s organs, such as the brain, skin and bones, for months to years after receiving the drug.
Exposure to gadolinium-based contrast agents has adverse side effects. Patients with Gadolinium Deposition Disease experience:
- Persistent burning or cutting sensation in the lower arms and lower limbs.
- Pain in bones and joints
- Head and neck pain
- Tightness in hands and feet
- Mental confusion, or brain fog
- Persistent headaches
- Vision and hearing problems
- Loss of hair
- Itchy skin
- Breathing problems
For years, the makers of gadolinium-based contrast agents may have been aware of the risks associated with the MRI drug. However, the continuously failed to warn the public. As a result, people are suffering from rare, incurable conditions. The Carlson Law Firm believes in holding drug manufacturer accountable for their actions. Contact our firm to schedule a free consultation with a Gadolinium lawyer.